Dermatology marketing agency for US practices — HIPAA-safe, 50-state medical board-compliant, Dallas-headquartered
Ichelon Global is a dermatology marketing agency headquartered in Dallas, Texas, running patient acquisition and referral development for medical and cosmetic dermatology practices across all 50 US states. Every campaign is scoped inside a HIPAA + TCPA + FTC + FDA + state-medical-board envelope. Search, paid, YouTube, GMB density, and reputation delivered on one stack, from a healthcare-only team that lives inside the same regulatory reality your practice does.
Backed by App\Support\NamedExperts::get(). --}}
- Ichelon Global is a Dallas-headquartered dermatology marketing agency serving US practices from single-provider clinics to PE-backed multi-state dermatology platforms across California, Texas, Florida, New York, Georgia, Arizona, Tennessee, Illinois, Washington, Nevada and every other state where a licensed physician can advertise.
- Every engagement is scoped against HIPAA (OCR 2022/2024 tracking bulletin), TCPA (2024 FCC revocation updates), CAN-SPAM, ADA web accessibility, FTC 16 CFR §255 Endorsement Guides, FDA 21 CFR §202.1 on prescription drug advertising, Meta Personal Attributes policy and the state medical board rules of every state the practice operates in.
- Retainers are custom-scoped per practice, typically $2,500 to $8,000 per month, plus creative and media pass-through. Angryturtle (GBP density SKU) runs in parallel for multi-location dermatology groups.
- Delivery stack covers organic search, Google Ads, Meta Ads, Google Business Profile density across every clinical address, YouTube provider-authority (YODA), reputation cross-monitoring, and CRM attribution back to booked visits.
A dermatology marketing agency built to work across all 50 US states, not retrofitted for one metro
A dermatology marketing agency runs the full patient-acquisition motion for a dermatology practice — medical, surgical and cosmetic — inside a compliance envelope that is tighter than most general-medicine practices realise. In the United States, that envelope has four layers that never move: HIPAA at the federal privacy level, FTC at the truthful-advertising level, FDA on any prescription-drug or medical-device claim, and the individual state medical board that licensed the physician. Add TCPA on outreach, CAN-SPAM on email, ADA on web accessibility, and Meta's Personal Attributes policy on paid social, and you have the day-to-day operating envelope a US dermatology practice actually lives in.
Ichelon Global was set up in Dallas to serve US healthcare with a compliance-first delivery spine that scales across state lines without breaking. Our office at 3714 Matador Dr sits inside the Central time zone that most US dermatology groups already run leadership calls on, and Santosh Reddy leads our US practice from the same address. But this is a national engagement — the Dallas HQ is where our US delivery pod sits, not a limitation on which practices we serve. We currently run active engagements for practices in Texas, California, Florida, New York, Georgia, Arizona, Tennessee, Illinois and Washington, and we scope net-new engagements for any state where a licensed dermatologist can advertise under their board's rules.
The reason a national flagship page exists at all is that most US dermatology practices no longer live in one state. Multi-location dermatology groups now routinely operate across two, three or five states — a Texas-headquartered group with Colorado and Tennessee locations, a Florida platform with Georgia and North Carolina expansion, a California network with Arizona and Nevada satellites. Each state adds a distinct medical board rule set, a distinct advertising review posture, a distinct patient litigation risk profile. A generalist marketing agency treats "US dermatology" as one market. It is not — it is fifty markets under one federal umbrella, and the practice that treats it accordingly earns compounding SEO and paid efficiency that a state-agnostic competitor never catches.
Ichelon Global runs your US dermatology engagement with a state-by-state creative review layer, a federal-compliance approval workflow, and a single delivery pod that owns the whole stack — SEO, paid, GBP density across every clinical address, YouTube provider-authority publishing, and reputation management. That is what separates us from a US general performance agency that added a healthcare vertical and hopes their playbook survives the first OCR bulletin update.
The US dermatology and aesthetic market — the numbers that shape the strategy
A national dermatology marketing strategy has to start from the actual size and shape of the US market. Not from what worked in one metro. Not from what a competitor said in a case study. From the underlying practice-count, revenue-tier, and growth data.
The US dermatology practice count spans 13,774 clinical locations across all 50 states and DC. The US medical spa count is a separate 10,488 locations, growing at a faster clip than dermatology itself as GLP-1-adjacent aesthetic demand pulls new capital into the category. The wider US aesthetic market — which includes injectables, energy-based devices, cosmeceuticals, and cash-pay cosmetic dermatology — grew to $9.46B in 2024 and is projected to reach $17.45B by 2030, a compound growth path that gives even a well-run practice a five-year window to compound share before market maturity flattens the curve.
Where that growth actually lives is not evenly distributed across the map. Four state-level realities shape a US dermatology marketing plan today:
- California is the largest US dermatology market by practice count. 1,743 dermatology practices, roughly 12.6% of the national footprint, concentrated across Los Angeles, San Francisco, San Diego, Orange County and the Bay Area's East Bay expansion. California's cosmetic buyer density, its Bus & Prof Code §17500 truthful-advertising rules, and its Medical Board §2261 supervision structure combine to make it the most rewarding — and the most compliance-heavy — state to compete in.
- Texas is the largest US med spa market and the second-largest dermatology market. 342 med spas and roughly 1,180 dermatology practices, weighted heavily to Dallas-Fort Worth, Houston, Austin and San Antonio. Texas Medical Board Rule 165.5 governs testimonials and before/after photography across the whole state, and the DFW aesthetic corridor concentrates a disproportionate share of the cash-pay cosmetic dermatology revenue in the state.
- Florida is the third-largest cosmetic dermatology market. Miami, Fort Lauderdale, Palm Beach, Tampa and Orlando anchor the state's aesthetic economy, with Florida Statute 458.351 governing physician advertising and a market that skews strongly to injectables, laser resurfacing, and post-weight-loss skin-tightening. The Miami cosmetic dermatology buyer is arguably the most sophisticated in the country, and the paid-media CPCs reflect that.
- The rising-metro cohort is Scottsdale, Nashville, Atlanta, Austin and Charlotte. These five metros grew dermatology and med spa density fastest between 2020 and 2025, and each carries a distinct compliance and demand profile that a national strategy has to price separately.
The top-demand US dermatology markets by paid-media auction pressure and organic search competitiveness are Miami, Los Angeles, New York, Atlanta, Scottsdale and Nashville. A national dermatology marketing plan that budgets to a US-wide average CPC will overspend in the mid-tier metros and underspend in the top six — which is where a specialist national agency earns its fee by moving budget to the metros where a $150 CPC still returns a positive booked-visit LTV, and away from metros where a lower-nominal CPC still fails to convert.
State medical board rules on dermatology advertising — the 50-state compliance matrix
Every US dermatology practice advertises under two layers of medical board rules: the federal envelope described below, and the individual state medical board that issued the physician's license. Below is the condensed 50-state matrix Ichelon Global works from. This is the operating map, not a legal opinion — every practice's specific facts should be reviewed by its own healthcare counsel before creative deployment.
| State | Governing rule / statute | Key stance on advertising |
|---|---|---|
| Texas | TMB Rule 165.5 & 165.1 | Written patient consent required for every testimonial and before/after image; no false, deceptive, or misleading claims; superiority claims require verifiable methodology. |
| Florida | Florida Statute 458.351 | Ban on deceptive advertising, mandatory disclosure of physician's medical qualifications, licensed name required in ads, before/after imagery must reflect typical results. |
| California | CA Bus & Prof Code §17500 + Medical Board §2261 | Broadest truthful-advertising rule in the US; no misleading testimonials; disclosure of before/after being non-typical; strict on "board certified" claims. |
| New York | NY Education Law §6530 | Professional misconduct rules cover any false, fraudulent or deceptive advertising by a licensed physician; strong on superiority claim substantiation. |
| Georgia | GA Code §43-34-8 | Requires truthful, current-standard-of-care representation of results; no comparative superiority without objective basis. |
| Arizona | AZ Rev Stat §32-1454 | Testimonials must be honest and current; before/after must not misrepresent typical outcome; strict on injectable off-label promotion. |
| Tennessee | TN Code §63-6-214 | Deceptive advertising is unprofessional conduct; testimonials without disclosure of compensation prohibited. |
| Illinois | IL Medical Practice Act §225 ILCS 60 | Strict on advertising outcomes as guarantees; before/after images require typical-results disclaimer where applicable. |
| Washington | WA Medical Practice Act RCW 18.71 | Broad prohibition on false, fraudulent, misleading or deceptive statements in advertising. |
| Massachusetts | 247 CMR 3.05 / MBRM guidance | Advertising must be verifiable, current, and not create unjustified expectation; strict on superlative claims. |
| Pennsylvania | 49 Pa Code §16.61 | Bans deceptive statements, requires substantiation of claims, physician-name attribution required. |
| Ohio | Ohio Rev Code §4731.22 | Deceptive advertising is grounds for licensure action; testimonial and photo consent expected. |
| North Carolina | NC Gen Stat §90-14 | Board discipline for false, misleading or deceptive advertising; scrutiny on injectable and laser claims. |
| Colorado | CO Rev Stat §12-240-121 | Truthful advertising required; results-based claims must be substantiated and reflect typical outcome. |
| Virginia | 18VAC85-20-30 | Prohibits testimonials that are misleading, fabricated, or misrepresent the endorser's actual experience. |
| New Jersey | NJ Admin Code 13:35-6.10 | Bans use of unearned or misleading credentials; strict on "specialist" and board-certification language. |
| Michigan | MI Comp Laws §333.16221 | False advertising is a violation of the Public Health Code; scrutiny on unsubstantiated superiority claims. |
| Nevada | NV Rev Stat §630.304 | Deceptive or misleading advertising is grounds for board action; injectable claims subject to on-label review. |
| All other states | State-specific board rules apply | Every remaining state has a materially similar deceptive-advertising prohibition. Ichelon Global scopes creative against the actual current rule and interpretive guidance of the state your provider is licensed in. |
For multi-state dermatology groups, we maintain a per-state creative review checklist that runs against every campaign asset — website copy, paid creative, GBP posts, Instagram carousels, YouTube titles, review-response templates — before it goes live in that state. A single national creative that reads clean in Texas can trigger a Florida deceptive-advertising complaint if the results language is not appropriately hedged for the Florida Statute 458.351 standard. The cost of that mistake is not the creative rework — it is the board complaint, the licensure defence, and the reputational surface area that follows.
HIPAA, TCPA, CAN-SPAM, ADA, FTC, FDA — the federal envelope every US dermatology campaign runs inside
Above the state medical board layer sits a federal envelope that applies uniformly across all 50 states. A US dermatology marketing plan that does not scope against every framework below is not a plan — it is an exposure profile.
HIPAA (OCR 2022/2024 tracking bulletin)
Condition and provider information passed to a third-party analytics or ad platform can constitute PHI when tied to an individual identifier. Every US dermatology engagement starts with a PHI scrub across GA4, Google Ads conversions, Meta CAPI, TikTok Events API, Clarity, Hotjar, LiveChat and every third-party embed on the practice website. BAA-ready with every partner that requires one.
TCPA (2024 FCC revocation updates)
The Telephone Consumer Protection Act carries $500 to $1,500 statutory damages per violating message. Every lead-form disclosure, appointment-reminder SMS, patient-education drip, and reactivation outreach is audited against the current TCPA rule set including the 2024 revocation-of-consent updates.
CAN-SPAM Act
Every US dermatology email marketing program is scoped for accurate sender identification, honest subject lines, physical postal address disclosure, and functioning one-click unsubscribe. Applies to newsletter, patient education, appointment reminder and reactivation flows.
ADA (web accessibility)
Dermatology websites are Title III places of public accommodation. WCAG 2.1 AA is the operative accessibility floor. We audit new-build and legacy dermatology websites against WCAG 2.1 AA (colour contrast, alt text, keyboard navigation, ARIA labelling) as part of engagement onboarding.
FTC 16 CFR §255 (Endorsement Guides)
Any influencer collaboration, aesthetician-referred client story, or incentivised Google review triggers the FTC Endorsement Guides. Material connection disclosure, honest depiction of results, and truthful representation of the endorser's actual experience are all in scope. We do not run influencer or review-incentive programs without an FTC-compliant disclosure structure built in.
FDA 21 CFR §202.1 (prescription drug advertising)
Any promotional communication that mentions Botox, filler brands, prescription cosmeceuticals, or the on-label vs off-label boundary is subject to FDA prescription drug advertising rules. Fair balance, indication accuracy, and risk information disclosure are scoped into every relevant creative asset before publication.
Meta Personal Attributes policy
Meta's ad-review system rejects creative that implies knowledge of a person's medical condition, appearance, or health status. Dermatology creative that reads clean to a human reviewer can trigger a Personal Attributes rejection at scale. We rewrite creative pre-flight against the current Meta policy interpretation and monitor account-level policy risk continuously.
Google Healthcare and Medicines policy
Google Ads restricts prescription-drug promotion, requires LegitScript certification for certain healthcare categories, and applies personalisation restrictions to health-related audiences. Every US dermatology Google Ads engagement is set up under the correct policy classification from account creation.
What the monthly stack actually delivers for a US dermatology practice
Every dermatology engagement runs on the same six delivery layers, weighted per practice. A single-location cosmetic dermatology practice in Beverly Hills weights heavier on paid social and reputation; a five-location dermatology group in Texas weights heavier on GBP density and organic search; a medical-dermatology-only practice weights heavier on referral SEO and directory optimisation; a multi-state PE-backed platform weights heavier on per-location P&L attribution and CRM-integrated reporting.
1. SEO — medical + cosmetic keyword clusters
Two separate topic maps: medical dermatology (acne, eczema, psoriasis, skin cancer, Mohs, biopsy) tied to insurance-taking intent; cosmetic (Botox, filler, laser resurfacing, IPL, chemical peel, microneedling) tied to cash-pay intent. Site architecture separates the two so paid amplification and content depth compound in the right direction. National groups add state-level and city-level content clusters as a third layer.
2. Paid — Google + Meta + LSA where eligible
Google Ads on branded and non-branded intent, geo-fenced to the ZIP-code catchments each provider actually sees patients from. Local Service Ads where the practice qualifies. Meta Advantage+ campaigns for cosmetic-only intent with HIPAA-scoped audience construction and TCPA-safe lead-form consent language.
3. GBP density — per location, per state
Angryturtle-run GBP for every clinical address the practice operates from. Post cadence, review response, Q&A seeding, service catalogue depth, and photo hygiene — all scoped to the state medical board's testimonial rules. Multi-location dermatology groups get consolidated review monitoring with per-location alerting.
4. YouTube provider-authority (YODA)
Long-form provider-authority publishing that positions the practice's dermatologists as the citation surface for AI Overviews and PAA panels on US dermatology queries. Also serves as the referral-partner briefing library for primary care groups, dental practices, and med spas that route to your practice.
5. Reputation cross-monitoring
Google, Healthgrades, RealSelf, Vitals, Zocdoc, Yelp (medical listings), and Reddit condition-specific subreddits. Review-request cadence tied to satisfied-patient triggers with Rule-165.5-equivalent state consent capture. Negative-review response templates cleared by state creative review before deployment.
6. CRM attribution & booked-visit reporting
Monthly reporting that ties channel spend to booked visits — not just to clicks or form fills. CRM integration where the practice runs one; call-tracking with HIPAA-scoped recording where they do not. Per-location, per-provider, per-service P&L attribution for multi-location groups.
The US dermatology buyer journey — and where marketing changes the outcome
US dermatology patients move through a buyer journey that rhymes across metros but changes in emphasis depending on the local aesthetic maturity, insurance mix, and referral-network density. A national marketing plan has to hold the same underlying journey and vary the delivery weighting per metro.
Stage 1 — Symptom or aspiration recognition
Medical dermatology enters through a symptom trigger — a mole change, a persistent acne flare, an eczema outbreak, a scalp condition, a lesion flagged by a primary care physician. Cosmetic enters through an aspirational trigger — a wedding, a reunion, a post-baby body goal, a GLP-1 loss that revealed loose skin, a peer's Botox result at a social occasion. The marketing job at this stage is to be findable on the specific query language the patient actually uses, in the specific metro they live in, on the specific device (mobile-first for aesthetic, mixed for medical) they are researching from.
Stage 2 — Provider comparison
US dermatology patients compare providers across three surfaces: Google (organic + reviews + Business Profile + AI Overviews), a specialty directory (Healthgrades and Zocdoc for medical, RealSelf for cosmetic), and social (Instagram for cosmetic, TikTok for injectables and GLP-1-adjacent skincare). The comparison window is measured in days, not weeks — US patients decide fast, especially in aesthetic. Your job is to be findable on all three surfaces with review density and creative depth that reads as "the obvious choice" in under two minutes of the patient's attention span.
Stage 3 — Booking trigger
The booking trigger differs sharply by intent type. Medical patients book from a "call the office" instinct on a symptom escalation, especially insurance-verified appointments. Cosmetic patients book from a "book online now while I'm on the site" instinct on aspirational intent. A dermatology practice website that only offers one of the two booking paths loses the other cohort. We build dual-path booking flows — call-first for medical urgency, online-book-first for cosmetic — with HIPAA-scoped analytics on both.
Stage 4 — First visit and ascension
Post-visit is where a US dermatology practice's LTV is decided. A cosmetic patient who visited for Botox will spend three to five times the initial visit revenue over eighteen months if the practice's post-visit journey introduces them to complementary services (filler, laser, medical-grade skincare regimens) with state-compliant education, not sales scripts. We scope post-visit journeys as part of the acquisition engagement because acquisition ROI without ascension design is a leaky pipe on any US dermatology P&L.
What a US dermatology marketing engagement costs — and what CPQL to expect per metro
Retainers are custom-scoped per practice against provider count, location count, state footprint, service catalogue breadth, and desired share of the metro market. There are no packaged tiers because a solo cosmetic dermatologist in Scottsdale does not need the same stack as a five-state dermatology platform with a Miami flagship.
Practical retainer ranges by practice profile:
- Solo cosmetic dermatology practice, one high-CPC metro location — $2,500 to $4,500/month. SEO + GBP + one paid channel (usually Meta on cosmetic intent), monthly reporting, quarterly strategy review with the leadership team.
- Two-to-three location medical + cosmetic dermatology practice, single state — $4,500 to $6,500/month. Full SEO stack across medical and cosmetic clusters, GBP density per location, Google + Meta paid, reputation cross-monitoring, YouTube provider-authority pilot.
- Multi-state dermatology group or PE-backed platform — $6,500 to $8,000+/month. Full stack plus per-location, per-state P&L attribution, per-provider content publishing, national SEO across every state the group operates in, and CRM integration for true cost-per-booked-visit reporting.
Media spend runs pass-through and is scoped separately, typically $3,000 to $40,000 per month depending on ambition and the number of markets in play. Product SKUs like Angryturtle ($12/month per location for GBP OS) run in parallel where per-location density is the acquisition constraint.
National CPQL benchmarks — cost per qualified lead by metro cohort
Cost per qualified lead varies by metro, service, and campaign maturity. The ranges below are mature-campaign benchmarks Ichelon Global operates against across our current US book, not first-90-day exploration numbers.
- Cosmetic dermatology — top-CPC metros (Miami, Beverly Hills, Manhattan, Scottsdale). Botox and filler intent typically returns $65 to $140 per qualified lead. Laser resurfacing and body contouring runs $140 to $280 because the buyer research window is longer.
- Cosmetic dermatology — mid-CPC metros (Dallas, Houston, Atlanta, Nashville, Austin). Botox and filler intent typically returns $45 to $95 per qualified lead. Laser and body contouring $110 to $220.
- Cosmetic dermatology — emerging metros (Charlotte, Raleigh, Denver, Portland, San Antonio, Kansas City). Botox and filler intent typically returns $35 to $75 per qualified lead. Laser and body contouring $85 to $180.
- Medical dermatology. Generally not scoped as a paid-lead motion — organic and referral rails dominate that intent set. Where paid runs (skin cancer screening awareness, insurance-taking practices actively growing panel), $25 to $60 per qualified lead is the operating range in most metros.
City-level dermatology pages Ichelon Global maintains — the national cluster
This flagship page consolidates the semantic cluster of city-level dermatology marketing pages Ichelon Global maintains across the US. Each metro page below carries its own state medical board scoping, its own paid-media CPC calibration, and its own submarket-level demand data. Practices researching us should read the metro page for their own market alongside this national flagship.
Not listed above? We take on new-market engagements every quarter. If your practice operates in a metro that does not have a dedicated Ichelon Global page yet — Chicago, Boston, Seattle, Denver, Minneapolis, San Diego, Philadelphia, Charlotte, Portland, Salt Lake City, and dozens more are actively serviced without a dedicated landing page yet — the delivery stack and pricing are identical. Scope a call and we will confirm state medical board coverage, paid-media benchmarks, and delivery-team allocation before any commercial commitment.
Search Intelligence Trifecta — organic and paid on one national stack
Every US dermatology engagement runs on the Search Intelligence Trifecta — Angryturtle, SIE and YODA. Paid acquisition buys the query today; SIE earns the ranking tomorrow so the same query is free next quarter. YODA builds the dermatologist-authority library that pulls in both patient search and referral-partner trust. Angryturtle keeps every US clinical address dense on Google Maps.
Angryturtle · GBP OS for every US location
Post cadence, review response, Q&A seeding, photo hygiene, service catalogue depth — scoped to each state's testimonial rules. Multi-location dermatology groups get consolidated review monitoring across every clinical address. Solo plan from $12/month per location; agency-managed plans priced separately.
SIE · Search Intelligence Engine
Topic map, entity graph and internal-link engineering around US dermatology query patterns. Content briefs optimised for AI Overview citation and PAA answer boxes on medical and cosmetic dermatology intent across state, metro and neighbourhood-level queries.
YODA · YouTube AIO for dermatology
Provider-authority builds — condition explainers, treatment overviews, before/after case discussion with state-board-compliant framing. Optimised for AI Overview citation and YouTube's recommendation engine. Doubles as the referral-partner briefing library.
US dermatology marketing — national-scope questions
How does Ichelon Global handle multi-state HIPAA compliance for national dermatology practices?
HIPAA is a federal rule, so the operating standard is the same in all 50 states — the 2022 OCR Bulletin and its 2024 update on tracking technologies govern how analytics, conversion pixels, session recording and third-party embeds handle any information that could constitute PHI when tied to an identifier. Where multi-state complexity actually enters is in state medical board rules layered on top. We run a single federal-compliance scope for the whole practice and then a state-by-state creative review layer for every state the practice is licensed in. Multi-state dermatology groups get a per-state creative review checklist that fires against every new asset before deployment in that state.
What is the typical CPQL range for dermatology marketing across US metros?
Cosmetic dermatology CPQLs in mature campaigns run $35 to $75 in emerging metros, $45 to $95 in mid-CPC metros (Dallas, Houston, Atlanta, Nashville, Austin), and $65 to $140 in top-CPC metros (Miami, Beverly Hills, Manhattan, Scottsdale). Laser and body-contouring CPQLs are roughly double injectables within the same metro tier because buyer research windows are longer. Medical dermatology is generally organic-and-referral led, not paid-lead led, but where paid runs the operating range is $25 to $60 per qualified lead in most metros.
Do you serve US dermatology practices outside Texas, California, Florida and New York?
Yes. We currently run engagements across states including Georgia, Arizona, Tennessee, Illinois, Washington, Colorado, North Carolina and Massachusetts, and we scope net-new engagements for any state where a licensed dermatologist can advertise. Not having a dedicated metro landing page for a market does not mean we do not serve it — the delivery stack and pricing are identical. Scope a call and we will confirm state medical board coverage and delivery-team allocation.
How does the Dallas HQ actually work for a practice on the other side of the country?
Dallas is where our US delivery pod sits — leadership, senior strategy, creative direction and reporting. Central time zone gives us a working overlap with every US metro. Client calls happen on Google Meet or Zoom; reporting is asynchronous and on-demand; senior team travel to on-site strategy sessions is scoped where the engagement warrants it. Practices in California, Florida, New York and every other state we serve get the same senior attention as practices in DFW itself — the physical office location is the compliance and delivery anchor, not a limitation on client geography.
Can Ichelon Global integrate with our existing PMS, CRM and call-tracking systems?
Yes. Standard US dermatology tech-stack integrations we work with include Epic, Athena, DrChrono, ModMed, Nextech, PatientNow, HubSpot (marketing), and any HIPAA-BAA-covered call-tracking provider. Where a practice runs a custom or in-house PMS, we scope the integration through your IT team's requirements. All CRM/PMS integrations are BAA-covered and audited for PHI leakage before campaign launch.
What happens if a state medical board or the FDA changes its advertising guidance mid-engagement?
Campaigns are re-scoped rather than left on old assumptions. The OCR tracking bulletin update in March 2024 is a good example — every active US dermatology engagement had its analytics and pixel scope reviewed and updated inside the first two weeks of guidance publication. State medical board rule changes are monitored per licensing state; FDA advertising guidance is monitored across every campaign that touches injectables or prescription cosmeceuticals. The scope-versioning workflow is included in the retainer, not billed separately.
Do you run separate creative for medical dermatology versus cosmetic dermatology on the same practice?
Yes, and this is central to how the engagement is scoped. Medical dermatology creative is educational-first, insurance-verification-friendly, and tuned to referral-partner discovery paths. Cosmetic dermatology creative is aspirational-first, cash-pay-friendly, and tuned to social-driven discovery paths. Splitting them into two topic maps under one delivery engagement — rather than running two agencies — avoids conflicting site architecture, competing internal-link priorities, and duplicated GBP effort.
How do you handle Meta Ads Personal Attributes policy rejections on dermatology creative?
Meta rejects dermatology creative that implies knowledge of a person's medical condition, appearance, or health status — even when the creative is technically compliant with FTC and state medical board rules. We rewrite creative pre-flight against the current Meta policy interpretation, monitor account-level policy risk continuously, and structure campaigns to reduce the surface area for cascading account-restriction risk. Where a rejection does occur, we appeal through official Meta channels rather than resubmitting the same creative under a different account.
Scope your US dermatology marketing engagement
Book a 30-minute scoping call with a member of the Leadership Team, email Santosh (Dallas HQ) directly, or WhatsApp us. Central time zone hours, same day where we can.
Adjacent US aesthetic and cosmetic pillar pages
Healthcare brands ICG
has worked with.
A representative slice of the 300+ healthcare brands ICG has delivered for across India. Full client list available under NDA during a Brand and Growth Diagnostic.
